Recent years have seen significant advancements in liquid biopsy techniques,especially in the use of circulating tumor DNA (ctDNA),guiding personalized treatment and comprehensive management of cancer patients.Improvements in detection techniques,specifically in sensitivity and precision,have opened up new possibilities for monitoring minimal residual disease (MRD),predicting relapse and refining treatment strategies.This paper will focus on the clinical application and research advancements of MRD in liquid biop-sies for early,locally advanced,and advanced lung cancer patients,while also looking towards future prospects and potential challenges in lung cancer MRD detection.
维普
万方数据